Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-K/A
2022 FY
Annual report (amended)
21 Jul 23
ARS
2022 FY
Annual report to shareholders
15 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K/A
2022 FY
Annual report (amended)
27 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
Current reports
8-K
Regulation FD Disclosure
24 Apr 24
8-K
Results of Operations and Financial Condition
28 Mar 24
8-K
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
20 Mar 24
8-K
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
6 Mar 24
8-K
Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate Presentation 1
28 Feb 24
8-K
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
6 Feb 24
8-K
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
29 Nov 23
8-K
Departure of Directors or Certain Officers
21 Nov 23
8-K
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
15 Nov 23
8-K
Femasys Inc. Announces Financial Results for the Third Quarter Ended
14 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
5 Apr 24
S-8
Registration of securities for employees
5 Apr 24
424B3
Prospectus supplement
8 Dec 23
S-3
Shelf registration
30 Nov 23
D
$6.85 mm in debt / options / securities to be acquired, sold $6.85 mm, 4 investors
22 Nov 23
424B3
Prospectus supplement
3 Oct 23
424B3
Prospectus supplement
14 Jul 23
S-1/A
IPO registration (amended)
7 Jul 23
S-1
IPO registration
23 Jun 23
424B3
Prospectus supplement
20 Apr 23
Other
EFFECT
Notice of effectiveness
11 Dec 23
CORRESP
Correspondence with SEC
6 Dec 23
UPLOAD
Letter from SEC
5 Dec 23
EFFECT
Notice of effectiveness
17 Jul 23
CORRESP
Correspondence with SEC
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
18 Jun 21
CERT
Certification of approval for exchange listing
17 Jun 21
Ownership
4
Richard D. Spector
13 Feb 24
3
Richard D. Spector
13 Feb 24
4
Daniel Scott Currie
2 Feb 24
4
Dov Elefant
2 Feb 24
4
Christine E Thomas
2 Feb 24
4
Kathy Lee-Sepsick
2 Feb 24
3
Initial statement of insider ownership
28 Nov 23
4
Joshua Silverman
22 Nov 23
3
Joshua Silverman
22 Nov 23
SC 13D
PharmaCyte Biotech, Inc.
22 Nov 23